Podcasts about guidelines

This podcast episode discusses the evolution and current state of battlefield medicine, focusing on the Tactical Combat Casualty Care (TCCC) guidelines, training tiers, and the importance of evidence-based practices. The conversation highlights the challenges faced in implementing these guidelines and the ongoing efforts to improve trauma care in combat situations. Key updates to the TCCC curriculum and the logistics of providing medical care in the field are also addressed, emphasizing the need for continuous improvement and adaptation in military medicine.Listen ad-free with a premium membership on Spotify, Apple Podcast, or Patreon.TakeawaysThe majority of casualties occur in the pre-MTF environment due to hemorrhage.Improvements in battlefield trauma care have led to increased survival rates.Evidence-based medicine is crucial for developing TCCC guidelines.The TCCC curriculum consists of four training tiers for different levels of medical personnel.Recent updates to TCCC guidelines focus on airway management and TBI care.Logistics remain a significant challenge in providing timely medical care in combat.The committee emphasizes the importance of adapting guidelines based on new evidence.Training for combat medics must prioritize effective interventions for hemorrhagic shock.There is a need for consensus on triage methods in mass casualty situations.Continuous updates and training resources are essential for maintaining high standards in military medicine.Chapters00:00 Introduction to Battlefield Medicine02:40 Guidelines and Evidence-Based Practices04:55 TCCC Curriculum and Training Tiers07:47 Updates and Changes in TCCC Guidelines10:21 Current Challenges and Future Directions13:05 TCCC and Evidence Grading15:42 Logistics and Implementation Challenges17:58 Conclusion and ResourcesThank you to Delta Development Team for in part, sponsoring this podcast.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠deltadevteam.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠For more content, go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.prolongedfieldcare.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Consider supporting us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/ProlongedFieldCareCollective⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.lobocoffeeco.com/product-page/prolonged-field-care

❌100% FREE VIDEO TRAINING (2025) ❌ New Method To Control Alcohol in 48 Hours ➡️ https://www.soberclear.com/video/?el=podcast

In this episode, Dr. Zachary Dietch, transplant surgeon at Northwestern Medicine, shares the remarkable case of a liver retransplant for a patient with a recent cancer history, made possible through innovative tools like organ perfusion and bypass techniques. He also discusses how Northwestern is helping to redefine transplant eligibility for cancer patients through data-driven, patient-centered decisions.

Dr. Lyudmila Bazhenova is back on the podcast to discuss the latest update of the living guideline on therapy for stage IV NSCLC without driver alterations. She shares the studies the Expert Panel reviewed in the first- and second-line settings, including NIPPON, HARMONi-2, and DUBLIN-3. Although these studies do not impact the existing guideline recommendations, Dr. Bazhenova provides context and comments on ongoing trials that will influence the next iteration of the living guideline. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1” at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01062 Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Lyudmila Bazhenova from University of California San Diego Moores Cancer Center, co-chair on "Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1." It's great to have you back on the show today, Dr Bazhenova. Dr. Lyudmila Bazhenova: It's my pleasure to be here. Brittany Harvey: And then before we discuss this guideline update, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Bazhenova, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into the content here, Dr. Bazhenova, this living clinical practice guideline for systemic therapy for patients with stage IV non–small cell lung cancer without driver alterations is updated on an ongoing continuous basis. So what prompted this latest update to the recommendations? Dr. Lyudmila Bazhenova: Living ASCO guidelines are designed to keep pace with rapidly evolving evidence that impacts treatment of our patients with lung cancer. As a committee, we are tasked with regular review of the published literature and determine if the new data warrants changes to existing recommendations. So in this recently published update, we evaluated new trials related to treatment of patients with metastatic lung cancer without driver alterations. Brittany Harvey: Excellent. Thank you for that explanation of the process. So, you just mentioned that the panel reviewed new trials for this update. So, which particular updated evidence did the panel review on first-line treatment options for patients with good performance status across histology and PD-L1 expression status, and how did this impact the recommendations? Dr. Lyudmila Bazhenova: For the first-line treatment option for patients without driver alterations, two studies met our criteria for review. One was the NIPPON trial from Japan, the second was the HARMONi trial. None of those two trials resulted in change in our guidelines, but I think they are giving us some additional information that would be useful for the way we treat patients with non–small cell lung cancer without driver alterations. For example, if we take those patients, we currently have several treatment options as a first line. One is monotherapy immunotherapy. You can give pembrolizumab as an example, and that was based on the KEYNOTE-024 and KEYNOTE-042 trials. Then we have a platinum doublet plus immunotherapy, and there are several trials that did that pathway. And then we have also an option of giving our patients dual IO immunotherapy combination, such as CheckMate 9LA and POSEIDON. At this point, we do not have any randomized trials comparing those three treatment modalities head-to-head. And the NIPPON trial was interesting to us because it was the first trial to compare CheckMate 9LA regimen, which is again, dual immunotherapy plus chemo, versus KEYNOTE-189 or KEYNOTE-407, which is a chemotherapy plus immunotherapy. And as a result of the study, while chemotherapy plus ipilimumab-nivolumab led to numerically higher overall survival, the difference was not statistically significant. And what is concerning in that trial is that we saw a higher number of treatment-related death occurring in nivolumab and ipilimumab arm compared to the pembrolizumab-chemotherapy arm. As a matter of fact, the trial was terminated early because of the increased risk of death. If you look at the treatment-related death in CheckMate 9LA, the 9LA study reported the treatment-related death to be 2%, and then in the NIPPON trial, the treatment-related death was 7%. Why is that happening? It's really difficult to say. The study was done in Japan. Maybe there is some pharmacogenomic differences between global population and Japan population. But certainly the higher rate of adverse events needs to be taken into account. Another interesting thing about this trial is that it did not show any differences in a subset analysis for patients with squamous histology as well as PD-L1 negative tumor. So while this does not change our current guidelines and CheckMate 9LA treatment still remains an appropriate treatment option, it kind of raises the possibility that this combination could be associated with a higher toxicity. And we do have a randomized US-based trial that is ongoing, and we are hoping that eventually we will be able to answer that question after the trial will be completed. The second trial we reviewed is HARMONi-2. So HARMONi-2 was a randomized, double-blind study which is conducted primarily in China, looking at bispecific PD-L1 and VEGF antibody called ivonescimab. And that took patients who were PD-L1 positive, as defined as more than 1% expression, and patients were randomized to pembrolizumab versus bispecific ivonescimab. And the study was positive. It showed improvement in median progression-free survival of 11 months versus almost 6 months in bispecific versus pembrolizumab. There were, however, higher grade 3 events in the ivonescimab arm. At this point, we are not changing our recommendations because this trial was done in an ex-US population, and we are awaiting a similar trial ongoing in the United States before we change recommendations and decide if ivonescimab needs to be included in our guidelines. Brittany Harvey: This context is very helpful when clinicians think through the data behind these options. And it's important that the panel reviews this evidence, even if it doesn't prompt a change to the recommendations. And we'll await results of those trials that you mentioned to further inform this guideline. So then beyond those studies for first line, what updated evidence did the panel review for second-line and subsequent treatment options for patients with good performance status, and how did this impact the recommendations? Dr. Lyudmila Bazhenova: So for second line, only one trial met the criteria, and that was DUBLIN-3. DUBLIN-3 is a phase 3 single-blind randomized trial comparing docetaxel versus docetaxel plus plinabulin. And the study enrolled patients with second or third line. They have to have had platinum-based chemotherapy and progressed. Plinabulin is an interesting compound. It's a small molecule tubulin binder that prevents polymerization of tubulin and appears to impact dendritic cell maturation and T-cell activation. This study enrolled 559 patients, randomly assigned them to two groups. And one important information about this study is that was a study that was envisioned before immunotherapy became a standard mainstream treatment for first-line therapy. And only 20% of patients had prior PD-1 exposure. So therefore, the results of that study need to be taken into context of this population no longer existing in the United States because we use PD-L1 inhibitors in the first line. And we saw that interesting in the plinabulin arm had lower rates of neutropenia but higher rates of serious adverse events. And at this point, we are not changing our guidelines for mainly two reasons. Number one, low number of patients that received prior treatment with first-line immune checkpoint inhibitors, as well as a modest overall survival benefit of this trial. Brittany Harvey: Understood. I appreciate you describing that study as well and why that evidence didn't prompt a change to those particular recommendations. So then, what should clinicians know as they implement this living guideline, and how does this new evidence impact clinicians and patients? Dr. Lyudmila Bazhenova: At this point, none of the studies that we reviewed resulted in a change in guidelines. We are still waiting for more global results from some of the studies that I highlighted. It shows that there's still a lot of questions we need to be answering in those patients. And I'm hoping that with future clinical trials, we will be able to definitively maybe recommend one treatment over another. But at this point, all the treatments that I mentioned before remain appropriate for patients with stage IV non–small cell lung cancer without driver alterations. Brittany Harvey: Definitely. And then you just mentioned that there's still a lot of outstanding questions in this field. You've mentioned a couple different studies where we're awaiting evidence. Beyond those that you already mentioned, what is the panel examining for future updates to this living guideline? Dr. Lyudmila Bazhenova: Right now, our next task is to come up with a full guidelines update. ASCO have certain rules for the guidelines committee members. And so we are gearing for a full guideline update, which hopefully will be ready by the end of 2025. Brittany Harvey: Excellent. We'll look forward to that full update of the living guideline, and we'll still await results of these ongoing trials to further inform this living guideline. So I want to thank you so much for your work to rapidly and continuously update this living guideline, and thank you for the time today, Dr. Bazhenova. Dr. Lyudmila Bazhenova: My pleasure. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Dr. Joshua Reuss joints that podcast to discuss the latest changes to the living guideline on stage IV NSCLC with driver alterations. He discusses the new evidence for NSCLC with EGFR mutations and NRG1 fusions and how this impacts the latest recommendations from the panel. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1” at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01061 Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1." It's great to have you here today, Dr. Reuss. Dr. Joshua Reuss: Thank you. Happy to be here. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So to dive into what we're here today to talk about, Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non–small cell lung cancer with driver alterations is updated on an ongoing basis. So what prompted this latest update to the recommendations? Dr. Joshua Reuss: Yes, thank you. It's very important that we have living guidelines that are continuously updated. We obviously don't live in a static environment where things are non-changing, and we really need to apply the most up-to-date and current evidence to treat our patients with the most effective strategies, the most groundbreaking strategies. And so to have guidelines that can be disseminated, particularly these ASCO guidelines, to treating providers is incredibly important. So, with any of these updates, we review ongoing studies, published work, for the quality of evidence to see if it's something that warrants making adjustments to our guidelines or at least incorporating the information so that providers can review it and incorporate this into their own personal decision-making. So in this particular update, we reviewed evidence particularly pertaining to EGFR-mutated non–small cell lung cancer and non–small cell lung cancer harboring an NRG1 fusion. Brittany Harvey: Yes, certainly there's a lot of new evidence in the advanced non–small cell lung cancer field, and so we appreciate the panel's continuous review of this evidence. So then you just mentioned two separate areas where the panel reviewed new evidence. So starting with that first one, what updated evidence did the panel review on first-line treatment options for patients with EGFR alterations, and how did this impact the recommendations? Dr. Joshua Reuss: Yes, so advanced EGFR-mutated non–small cell lung cancer, at least with classical activating alterations - that is our exon 19 deletions and our exon 21 L858R mutations - is something that's really evolved rapidly in the last few years. You know, for many years, we basically, for the frontline treatment setting, were saying, "Okay, we have a targeted therapy, osimertinib. We're going to give that, and we're going to see what effect we can get out of that," with, you know, a median time of duration of treatment response averaging around 18 months, knowing that there are some that that's a lot longer and some that are a lot shorter. But recently, we've seen a lot of data emerging on combination strategies. The guideline has already been updated to incorporate two of these combinations: osimertinib with chemotherapy based off of the FLAURA2 trial, and then the combination of amivantamab with lazertinib based off of the MARIPOSA trial. And that was data on progression-free survival that was published and led to those particular recommendations. Now, more recently, we've seen data come out in smaller, randomized studies for other combinations. And more recently, we reviewed the RAMOSE study. So this was a phase II, open-label, randomized trial for patients with tyrosine kinase inhibitor–naive and really, treatment-naive advanced EGFR-mutated non–small cell lung cancer harboring one of these two classical EGFR alterations, randomized to either osimertinib alone or osimertinib with the combination of ramucirumab, which is an anti-VEGF agent. There's been a lot of data, preclinical and clinical, for the role of VEGF blockade, particularly in EGFR-mutated non–small cell lung cancer, so exploring the combination of this for synergy in the frontline setting really made a lot of sense. So again, this was a phase II trial that randomized patients prospectively to one of these two regimens. The population here is really what we typically see with EGFR-mutated non–small cell lung cancer, predominantly a younger population - median age on this study was 65 - predominantly female - 71% female - and predominantly nonsmokers. Now, what this study showed was that at a median follow-up of 16.6 months, the progression-free survival favored the combination arm with a median progression-free survival of 24.8 months with the combination of osimertinib plus ramucirumab versus 15.6 months for osimertinib alone, for a hazard ratio of benefit of 0.55. The landmark one- and two-year endpoints for progression-free survival also favored the combination arm, and response rates were relatively comparable between groups, with overall adverse events being more frequent in the combination group, specifically high blood pressure, proteinuria, and epistaxis, which are our common adverse events related to VEGF-blocking agents. So, it's good to see data in this space. Now, of note, though, this was a phase II study, so not a phase III level of evidence. In addition, when looking at the population, this was a randomized, multicenter study, but it was a US-only population. There was also some imbalance in the number of visits between arms, so the combination arm was seen more frequently than the arm that got osimertinib alone. Now, the imaging assessments were no different, but obviously this could lead to potential confounding, at least in timing of awareness of potential side effects and and things being brought to the attention of investigators. So very promising data here, but because, you know, of this being a phase II study, this actually led to no changes in the guideline at this time. Brittany Harvey: Understood. Yes, as you mentioned prior, it's important to understand the full body of evidence and to review the trials even when it doesn't impact the recommendations. Dr. Joshua Reuss: And I will say that, you know, there is an ongoing phase III study looking at a very similar combination. It's the phase III ECOG-ACRIN trial of the combination of osimertinib plus bevacizumab versus osimertinib alone in this specific population. So, you know, I think we will see phase III–level data for a combination of VEGF with osimertinib, but again, promising phase II data that did not lead to a change in the recommendation at this time. Brittany Harvey: Absolutely. We'll look forward to that ongoing trial to learn more about combination in this patient population. So then moving to that second patient population that you mentioned earlier where the panel reviewed evidence, what is the updated evidence and recommendation for patients with NRG1 fusions? Dr. Joshua Reuss: Yeah, so this was an exciting update that we made more recently with this unique iteration of the living guidelines. So, NRG1 fusions, this is perhaps a newer kid on the block in terms of driver alterations that has been known to be identified in non–small cell lung cancer among other solid tumors. It is very rare, occurring in less than 1% of solid tumors, but something that we know is a unique oncogenic pathway that can lead to oncogenesis and cancer development, including in non–small cell lung cancer. So up until now, unfortunately, there have not been targeted therapies that target this unique alteration. It's somewhat different than other driver alterations where there's a top-level signaling change in a protein. This is more of a ligand alteration that then alters, that then enables activation of more classical pathways, but again, through upregulation of a unique ligand. So a slightly different pathway but something that we know should be able to be targeted to promote patient survival for those with NRG1 fusions. So the therapy here is a therapy called zenocutuzumab. It's an IgG1 bispecific antibody against HER2 and HER3. So it prevents the downstream dimerization and signaling that occurs as a result of this NRG1 fusion and upregulation of the NRG1 signal. This was, as you can imagine with a rare alteration, a large phase II registrational study that examined this in advanced solid tumors containing the NRG1 fusion. This is the NRG1 registrational trial. And this study enrolled patients with advanced solid tumors who had progressed on prior therapy. Patients were treated with zenocutuzumab 750 milligrams IV every two weeks. Among 158 response-evaluable solid tumor patients, the response rate was 30%, median duration of response of 11.1 months, and a median progression-free survival of 6.8 months. Now, in those with non–small cell lung cancer, that made up 93 response-evaluable patients, very similar outcomes there: a response rate of 29%, median duration of response of 12.7 months, and a median progression-free survival of 6.8 months. This therapy did appear to be well tolerated. The most common higher-grade emergent side effects - grade 3 or higher - were anemia occurring in 5% and elevated liver numbers occurring in 3%. So this is a subsequent-line study, so this led to the updated recommendation that clinicians may offer zenocutuzumab in the subsequent-line setting for patients with advanced non–small cell lung cancer who harbor NRG1 fusions. So I think this does speak toward the incredible importance of next-generation sequencing and molecular testing for patients, particularly to include testing that looks at the RNA. These large fusions can sometimes be very challenging to detect on DNA sequencing platforms alone, so it's important to, if you have a high level of suspicion for an alteration like this, perhaps some of the mucinous adenocarcinomas where it's been challenging to find a driver alteration, and it's someone who is a never-smoker, really would want to include molecular testing that assesses the RNA level and not just the DNA. Brittany Harvey: Absolutely. It's important to have all the biomarkers available so that clinicians are able to use that to inform their decision-making. So then, given these changes in the guideline, what should clinicians know as they implement this latest living guideline update? And how do these changes impact patients? Dr. Joshua Reuss: Yeah, I think talking in reverse order of what we just discussed here, there is a new guideline update for NRG1 fusions. So I think making sure that that's being evaluated, that clinicians are testing for that and really looking for that result that should be incorporated in in most next-generation large sequencing assays to get that result, but it's very important that that is not overlooked now that we do have a therapy that's available in the subsequent-line setting, though it is important to note that patients with NRG1 fusions, at least the limited data that there is suggests that the efficacy to standard chemoimmunotherapy regimens is overall poor. So physicians unfortunately might be facing this question for second-line therapy in patients with NRG1 fusions sooner rather than later. For the former, for EGFR-altered non–small cell lung cancer and how do we incorporate VEGF-containing regimens into these patients? Our guideline top-level update did not change based off of review of this new study, but it's important for clinicians to know what other combinations may exist. You know, there are phase III studies looking at this combination in the frontline setting. And of course, there is data on other bispecific molecules that incorporate VEGF in the subsequent-line setting, particularly a combination that includes the VEGF/PD-1 bispecific antibody ivonescimab that's being studied in the HARMONi-A trial for patients with EGFR-mutated advanced non–small cell lung cancer, for which we hope to get some more definitive data in the coming months. Brittany Harvey: Definitely. And then you've just mentioned a few ongoing trials where we're looking for evidence to inform future updates. But thinking beyond that, into the future, what is the panel examining for future updates to this living guideline? Dr. Joshua Reuss: It's a very exciting time to be in the world of treating advanced non–small cell lung cancer, particularly patients with driver alterations, because there is so much evolving data that's changing our practice in real time, again highlighting the importance of these living guideline updates. I'd say there's many things that we're excited to see. You know, a lot of the combination regimens in EGFR-mutated non–small cell lung cancer for which there are approvals and current recommendations in our guideline, particularly osimertinib plus chemotherapy and amivantamab plus lazertinib - those are the two approved combination strategies in the front line - we are now seeing the emergence of overall survival data for those combinations. So obviously that is something that's going to be very important for the committee to review and incorporate into guideline updates. There are several new therapies coming down the road for other driver populations. We recently saw an approval for taletrectinib for ROS1 fusion–positive non–small cell lung cancer, so it's going to be important that the committee reviews the data and the publications regarding that therapy. And then there are other novel therapies that we're looking to see updated data on. There are multiple antibody-drug conjugates, which take the potent power of a chemotherapy molecule and attempt to make that targeted with an antibody targeting to a unique feature on the cancer cell. And there are several antibody-drug conjugates that are in development at various levels of promise in this space, particularly in EGFR-mutated non–small cell lung cancer, and I anticipate seeing some emerging data for that coming up in the near future as well. So really, lots to be excited in the space and lots for our committee to review to give guidance on so that these patients can really receive the top-level care wherever they are being treated in the country and throughout the world. Brittany Harvey: Yes, we'll await this new data to continue to provide optimal options for patients with stage IV non–small cell lung cancer with driver alterations. So, Dr. Reuss, I want to thank you so much for your work to rapidly and continuously update and review the evidence for this guideline and thank you for your time today. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available on the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Are you confident when increasing the vertical dimension? How do you plan, stage, and sequence a full-mouth case safely? What's the right deprogramming method—leaf gauge, Kois appliance, or something else? Dr. David Bloom joins Jaz in this powerhouse episode to demystify the real-world process of increasing vertical dimension. With decades of experience in comprehensive dentistry, David shares how he approaches diagnosis, bite records, temporization, and final restorations—with predictability and confidence. https://youtu.be/gAaP0VYP84s Watch PDP232 on YouTube Protrusive Dental Pearl: Pick one occlusal philosophy and stick with it until you understand it well through real cases. Once you're confident, stay open to other approaches—hearing different views will make you smarter, more flexible, and a better dentist. If you are looking to get started with the foundations of Occlusion, check out our comprehensive Online Occlusion Course. Highlights of this episode: 00:00 Trailer 00:55 Introduction 04:43 Guest Introduction: Dr. David Bloom 10:25 Equilibration Techniques Explained 11:18  Interjection #1 15:50  Opening Vertical Dimension vs. Orthodontics 18:06 Interjection #2 23:05 Whitening and Restorative Solutions 25:27 Guidelines for Raising Vertical Dimension 25:52 Interjection #3 29:28 Midroll 32:49 Guidelines for Raising Vertical Dimension 36:06 Visual Try-In and Adapting Vertical Dimension 40:16 Case Planning and Execution 41:16 Interjection #4 43:42 Case Planning and Execution 50:23 Material Preference for Provisionals 52:00 Bite Registration and Final Adjustments 55:06 Do's and Don'ts for Clinicians 57:15 Conclusion and Resources 58:59 Outro Key Takeaways Vertical Dimension and Adaptation: Opening the vertical dimension in dentistry can be challenging, especially for edentulous patients who lack proprioception. However, with proper planning and understanding of occlusion, the human body can adapt remarkably well. Occlusal Philosophy: It's important to learn one occlusal philosophy well, whether it's Kois, Dawson, or another. Understanding different approaches can make you a more rounded clinician, as different patients may benefit from different methods. Equilibration and Deprogramming: Equilibration is crucial for idealizing occlusion by eliminating interferences. Deprogramming helps in achieving centric relation, a stable and repeatable position for the condyles, which is essential for successful equilibration. Orthodontics vs. Vertical Dimension: Deciding between orthodontics and opening the vertical dimension depends on the specific case. For example, pre-aligning patients with orthodontics might be necessary to address a restricted envelope of function. Testing and Adaptation: Testing the vertical dimension with transitional materials like composite can help patients adapt before moving to definitive restorations. Experienced clinicians may sometimes proceed directly to final restorations based on their judgment and diagnostic steps. Get CE/CPD for this episode only on the Protrusive Guidance App.

In this episode, we delve into the halachic complexities of dealing with small insects—specifically fleas and lice—on Shabbat. We explore when removing or killing them is permitted, distinguishing between pain-based allowances and general prohibitions. Learn key rulings from classic halachic sources and understand the rabbinic versus biblical distinctions regarding trapping and killing small creatures on Shabbat.

Welcome back to another episode of the Online Warriors Podcast! This week we have a very special episode! The gang talks about the latest in Gaming and Entertainment! - New Nintendo E-Shop Guidelines (4:01) - Borderlands 4 Character Drop (11:48) - Microsoft Shuts Down Perfect Dark and Everwilds (22:02) - The Last of Us Part 2 Chronological Release (30:02) Then we talk about what the gang has been up to: - Techtic watches Jurassic World Rebirth (37:02) - Nerdbomber watches Megan 2.0 (42:49)   Special shoutout to our Patreon Producer: Steven Keller!   We'd like to thank each and every one of you for listening in every week. If you'd like to support the show, you can drop us a review on your favorite podcast platform or, if you're feeling extra generous, drop us a subscribe over at Patreon.com/OnlineWarriorsPodcast. We have three tiers of subscriptions, each of which gives you some awesome bonus content! As always, we appreciate you tuning in, and look forward to seeing you next week! Stay safe and healthy everyone! Find us all over the web: Online Warriors Website: https://www.onlinewarriorspodcast.com Online Warriors Twitter: https://twitter.com/onlinewarriors1 Illeagle's Twitter: https://twitter.com/OWIlleagle86 Nerdbomber's Twitter: https://twitter.com/OWNerdbomber Techtic's Twitter: https://twitter.com/OWTechtic Facebook: https://www.facebook.com/onlinewarriorspodcast Instagram: https://www.instagram.com/onlinewarriorspodcast/ YouTube: https://www.youtube.com/channel/UCwOwzY6aBcTFucWEeFEtwIg Merch Store: https://onlinewarriorspodcast-shop.fourthwall.com/

NEWS: Comelec issues guidelines for voters' registration | July 16, 2025Subscribe to The Manila Times Channel - https://tmt.ph/YTSubscribe Visit our website at https://www.manilatimes.net Follow us: Facebook - https://tmt.ph/facebook Instagram - https://tmt.ph/instagram Twitter - https://tmt.ph/twitter DailyMotion - https://tmt.ph/dailymotion Subscribe to our Digital Edition - https://tmt.ph/digital Check out our Podcasts: Spotify - https://tmt.ph/spotify Apple Podcasts - https://tmt.ph/applepodcasts Amazon Music - https://tmt.ph/amazonmusic Deezer: https://tmt.ph/deezer Stitcher: https://tmt.ph/stitcherTune In: https://tmt.ph/tunein #TheManilaTimes#KeepUpWithTheTimes Hosted on Acast. See acast.com/privacy for more information.

  This month, we're diving in deep on the U.S. approval of lenacapavir for PrEP -- both the promise it offers in expanding HIV prevention options and the current uncertainty around access, both in the U.S. and abroad. We also discuss growing concern within the HIV clinical community that our gold-standard guidelines for HIV treatment, care, and prevention may be rousted loose from their long-standing home within the Office of AIDS Research at the U.S. National Institutes of Health. And Laura Waters shares what she's most eager to learn about at IAS 2025, the global HIV science meeting that is taking place as this episode drops.   Please support our podcast by visiting the transcript, which includes links to the many references we mention in this episode: https://www.thebodypro.com/podcast/hiv/future-hiv-care-lenacapavir-prep-guidelines-july-2025   The podfolx: Our co-hosts are Laura Waters, M.D., FRCP, and Myles Helfand; our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; our audio editor is Kim Buikema; and our executive producer is Myles Helfand.

Today's Topics: 1, 2, 3, 4) Association of Exorcists issues a document on errors it sees during exorcisms https://spiritdaily.org/blog/news/association-of-exorcists-issues-document-on-what-it-sees-as-errors

The BBC's Director General Tim Davie has apologised after a review found the Corporation failed to disclose that the documentary 'Gaza: How To Survive A Warzone' was narrated by the child of a Hamas official. Separately, the former Masterchef presenter Gregg Wallace said he was deeply sorry for any distress his behaviour caused after dozens of allegations against him were upheld. Also: Constance Marten and Mark Gordon are found guilty the manslaughter of their newborn daughter after a retrial. And a 61-year-old Flymo lawnmower is set to be inducted in a hall of fame.

The official guidance on low-risk drinking doesn't reflect modern scientific evidence and "understates the health risks" of alcohol, according to Health New Zealand documents released to RNZ. Guyon Espiner spoke to Corin Dann.

In this episode, Tyler sits down with Hanna Thompson to discuss a critical yet often overlooked topic in EMS—eating disorders. Drawing from personal experience and clinical insight, they explore how these conditions present both medically and behaviorally, especially in prehospital and interfacility transport settings. They break down the subtle physical signs that EMS providers can look for—such as Russell's sign, lanugo, unexplained bradycardia, and electrolyte disturbances—and emphasize the importance of sensitive history taking. The conversation also dives into the dangers of refeeding syndrome, slow correction strategies, fluid choice, and the clinical significance of thiamine, magnesium, and phosphate replacement. What You'll Learn: How eating disorders can manifest in EMS calls Why you may be treating the consequences, not the disorder itself Red flags like bradycardia, lanugo, and Russell's sign How to handle refeeding syndrome safely Why dextrose, fluids, and electrolyte replacement should be approached cautiously The connection between electrolyte shifts and seizures or arrhythmias Key Takeaway: Patients with eating disorders are medically and psychologically fragile. In EMS, we often encounter them through the effects of the disorder—not the diagnosis itself. Recognizing subtle clues and avoiding aggressive interventions could save a life. Resources Mentioned: Hannah's blog on EMS considerations in eating disorders Data on post-COVID spikes in eating disorder incidence Guidelines for electrolyte correction and refeeding syndrome Disclaimer: This podcast is for educational purposes only and not a substitute for clinical protocols or medical direction. Always consult your agency's guidelines and medical control.

Revoyez avec Pr Darrouzet, les points clefs à retenir concernant les diagnostiques à ne pas louper en pratique quotidienne de MG.Au cours de ce podcast, vous reverrez : ✅ Les drapeaux rouges neurologiques ?✅ Le HINTS test : pourquoi tout MG devrait savoir faire ce test ? Comment le faire en 1 min chrono.✅ Les 4 vertiges les + fréquents qui représentent >90% des cas.✅ Quel matériel acheter ?✅ Quand adresser chez l'ORL ?

In this BJSM podcast we are joined by Margie Davenport, lead author of the 2025 Canadian Guideline for Physical Activity, Sedentary Behaviour, and Sleep throughout the First Year Postpartum. This podcast provides crucial insights health and exercise professionals guiding new mothers and their support network through the return to physical activity. It highlights the importance of movement, individualized recovery, and sleep hygiene, all while addressing the unique challenges of postpartum life. Guidelines: https://bjsm.bmj.com/content/59/8/515 More about Margie's research lab: https://www.ksr.ualberta.ca/exerciseandpregnancy/ourLab.php

Pain during a cesarean section isn't a new problem. But for a long time, it's been a hidden one. In England, a patient named Susanna not only brings the problem to doctors' attention, but also tries to solve it. To get full access to this show, and to other Serial Productions and New York Times podcasts on Apple Podcasts and Spotify, subscribe at nytimes.com/podcasts.To find out about new shows from Serial Productions, and get a look behind the scenes, sign up for our newsletter at nytimes.com/serialnewsletter.Have a story pitch, a tip, or feedback on our shows? Email us at serialshows@nytimes.com

Michelle Wilson, Registered Dietician with Branz Nutrition, joins Megan Lynch with a look at the new nutrition guidelines that are set to be updated soon. https://www.branznutritioncounseling.com/

Have you ever wondered why so much prenatal nutrition advice seems outdated? Or why real, whole foods aren't at the center of it? In this episode of the NTI PodTalk, Dianne sits down with Lily Nichols, RDN, author of Real Food for Pregnancy and founder of the Institute for Prenatal Nutrition. Together, they explore why current prenatal nutrition guidelines often fall short — and how a real food, functional nutrition approach can better support pregnancy, postpartum, and breastfeeding health.About Lily Nichols:Lily Nichols is a Registered Dietitian/Nutritionist, Certified Diabetes Educator, researcher, and author with a passion for evidence-based nutrition. Her work is known for being research-focused, thorough, and sensible. She is the founder of the Institute for Prenatal Nutrition®, co-founder of the Women's Health Nutrition Academy, and the author of three books: Real Food for Fertility (co-authored with Lisa Hendrickson-Jack), Real Food for Pregnancy, and Real Food for Gestational Diabetes. Lily's bestselling books have helped tens of thousands of mamas (and babies!), are used in university-level maternal nutrition and midwifery courses, and have even influenced prenatal nutrition policy internationally. When she steps away from writing, you can find her spending time with her husband and two children — most likely outside or in the kitchen.Connect with Lily **Timestamps for the topics discussed can be found on this episode's NTI PodTalk page.Are you ready to start your journey as a Nutrition Therapist Master? To learn more about NTI's Nutrition Therapist Master Certification, visit ntischool.com for more information, or call 303-284-8361 to speak with our admissions team.This discussion is not intended to provide Medical Nutrition Therapy, nor in any way imply that Nutrition Therapists who graduate from NTI are qualified to provide Medical Nutrition Therapy. The scope of practice for graduates of NTI is to deliver therapeutic nutrition guidance to our clients which helps support their natural biology to achieve optimal function in whatever wellness path they are on.

Doctors Lisa and Sara take a deep dive into the recent combined asthma guidelines with Dr Murugesan Raja who is a GP and clinical lead for respiratory medicine for NHS Greater Manchester Strategic Clinical Network.  We go through the new asthma recommendations for the different age groups, starting with a reminder of what symptoms make up a typical asthma history, moving on to the new pathway of investigations, and ending with a chat about management covering AIR and MART.  We also touch on green prescribing, steroid cards and other important areas of management such as adherence and inhaler technique.   You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: Joint asthma guideline: https://www.nice.org.uk/guidance/ng244 GMMMG asthma guidelines: https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/gm-asthma-guideline-2024-for-web/ Asthma and Lung UK: https://www.asthmaandlung.org.uk/ Right Breathe: https://www.rightbreathe.com/ Asthma and Lung UK explainer videos: https://www.asthmaandlung.org.uk/living-with/inhaler-videos ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

Dr. Rob and Marriage and Family Therapist and CSAT Arlene Rosen continue their discussion about discernment counseling. They consider how to determine what each person needs throughout the collaborative divorce process, how to protect children and pets throughout the journey, and realistic timelines when addiction is a factor in a relationship. Arlene shares advice, resources, and a message of hope and healing in the collaborative divorce process.    TAKEAWAYS: [1:22] Determining what each person needs throughout the collaborative divorce. [5:42] Child welfare versus child safety in court order agreements.  [8:10] Timeline possibilities when addiction is at play.  [11:20] Handling chronic lying in a legal setting.  [15:55] A message of hope in the collaborative divorce process. [18:09] Is there a simple way to know that I should get divorced?  [23:00] Guidelines for an effective separation period.  [29:35] Determining the right next step based on your current stage of life.  [32:32] Navigating divorce in a non-legal partnership.    RESOURCES: Sex and Relationship Healing @RobWeissMSW Sex Addiction 101  Seeking Integrity Free Sexual Addiction Screening Assessment Partner Sexuality Survey Arlene Rosen Seeking Integrity Podcasts are produced in partnership with Podfly Productions.    QUOTES: “You can make agreements about what will be talked about your addiction in your divorce.”  “Why do more damage when you've decided not to live together anymore?”  “The collaborative divorce process is simply more respectful.”  “The collaborative divorce process has the most opportunity for people to get back together.”

❌100% FREE VIDEO TRAINING (2025) ❌ New Method To Control Alcohol in 48 Hours ➡️ https://www.soberclear.com/video/?el=podcast

Podcast: PrOTect It All (LS 26 · TOP 10% what is this?)Episode: How AI Became the Ultimate Cybersecurity Blind Spot: Understanding the Microsoft 365 Copilot VulnerabilityPub date: 2025-07-07Get Podcast Transcript →powered by Listen411 - fast audio-to-text and summarizationIn this episode, host Aaron Crow dives deep into the fast-evolving world of AI automation and its impact on cybersecurity. Aaron breaks down practical, real-world ways security professionals can leverage AI to streamline their workflows without breaking data loss prevention policies or putting proprietary information at risk.  From drafting reports and playbooks to automating repetitive tasks and managing vulnerability data, Aaron offers actionable advice for using both public AI tools like ChatGPT and more advanced private AI models. He also addresses common fears CISOs and business leaders have about unsanctioned AI use in the workplace and shares tips for staying safe and compliant while taking advantage of AI's efficiencies.  Whether you're in a large enterprise or a lean team with limited resources, you'll come away with a fresh perspective on how to use AI responsibly to work smarter and protect your organization. Plus, Aaron invites listeners to share their own creative AI use cases and lessons learned. Let's jump in and explore how to protect it all as AI advances. Key Moments :  01:20 AI's Rising Role in Media 03:22 Guidelines for Using AI Safely 07:06 "AI Integration and Automation Strategies" 10:03 Automating Windows Management Tasks 14:29 Exploring AI for Personal Tasks Connect With Aaron Crow: Website: www.corvosec.com  LinkedIn: https://www.linkedin.com/in/aaronccrow   Learn more about PrOTect IT All: Email: info@protectitall.co  Website: https://protectitall.co/  X: https://twitter.com/protectitall  YouTube: https://www.youtube.com/@PrOTectITAll  FaceBook:  https://facebook.com/protectitallpodcast    To be a guest or suggest a guest/episode, please email us at info@protectitall.co   Please leave us a review on Apple/Spotify Podcasts: Apple   - https://podcasts.apple.com/us/podcast/protect-it-all/id1727211124 Spotify - https://open.spotify.com/show/1Vvi0euj3rE8xObK0yvYi4The podcast and artwork embedded on this page are from Aaron Crow, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.

What would you do if your patient suddenly lost consciousness or went into cardiac arrest mid-procedure? In this high-stakes episode of Everyday Oral Surgery, Dr. Grant Stucki is joined by Drs. Andrew Jenzer and Elisa Hannan for a practical and insightful deep dive into managing medical emergencies in the office-based surgical setting. From syncope and seizures to bronchospasm, laryngospasm, and myocardial infarction (MI), they break down real-world scenarios, emergency algorithms, medication protocols, and critical decision points like when to activate emergency medical services (EMS). They also discuss nuances in pharmacology, airway management, and board prep strategies that can help you become a safer and more prepared surgeon. Whether you're a resident studying for boards or a seasoned practitioner looking to refine your emergency response, this conversation is packed with actionable guidance and clinical advice. Tune in to sharpen your skills and ensure you're ready when every second counts!Key Points From This Episode:Why board prep should include emergency scenarios.Knowing when and why to activate EMS.Guidelines for managing vasovagal syncope effectively.Signs and symptoms for identifying high-risk patients for syncope.Tips for recognizing and treating bronchospasm.Pros and cons of IV versus IM epinephrine for emergencies.Breaking laryngospasm with proper technique and preventing it during sedation.Strategies for managing seizures and airway support.Differentiating seizure-like activity and the importance of ABCDEFG.Practical lessons from real-life seizure emergency stories.Understanding MI symptoms and ONAM updates.Why drugs like nitroglycerin and morphine require caution.Managing intraoperative hypo/hypertension and drug choices based on heart rate.Variable approaches to the three levels of hypoglycemia.How doing mock cases and boards makes you a better surgeon.Links Mentioned in Today's Episode:Dr. Andrew Jenzer — https://surgery.duke.edu/profile/andrew-clark-jenzerDr. Andrew Jenzer Email — andrew.jenzer@gmail.com Dr. Elisa Hannan — https://www.avonomfs.com/elisa-b-hannan-dmd-mdAvon Oral, Facial, and Dental Implant Surgery — https://www.avonomfs.com/Dr. Elisa Hannan on LinkedIn —https://www.linkedin.com/in/elisa-hannan-66ba1530a/ Dr. Elisa Hannan Email — ebhannan@gmail.com St. Louis Oral & Maxillofacial Surgery Review — https://stlomfsreview.com/ Oral Board Review for Oral and Maxillofacial Surgery: A Study Guide for the Oral Boards — https://www.amazon.com/dp/3030488799 AAOMS Office Anesthesia Evaluation Manual — https://members.aaoms.org/PersonifyEbusiness/AAOMSStore/Product-Details/productId/1525502Everyday Oral Surgery Website — https://www.everydayoralsurgery.com/ Everyday Oral Surgery on Instagram — https://www.instagram.com/everydayoralsurgery/ Everyday Oral Surgery on Facebook — https://www.facebook.com/EverydayOralSurgery/Dr. Grant Stucki Email —

Shiur given by Rabbi Bezalel Rudinsky on Dvar Halacha Hashavas Aveida. Shiur recorded in Yeshivas Camp in New New Bloomfield, PA.

Sunday Service - June 22, 2025Matt RowanCTKGibsons.com

In this episode, UROONCO PCa chief editor Dr. Giancarlo Marra speaks to Prof. Derya Tilki (DE) about the 2025 updates in the EAU Prostate Cancer Guidelines, specifically regarding high risk, locally advanced disease and biochemical recurrence. This discussion includes changes such as the use of PSMA-PET-CT for staging, and updates related to lymphadenectomy. 

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 1738: Seth Godin invites readers to rethink how frequently they should share their work, emphasizing that the value of communication lies in consistency and relevance rather than volume. He highlights that building trust and connection comes from thoughtful, regular contributions that resonate with the audience, not from overwhelming them. Read along with the original article(s) here: https://seths.blog/2008/09/how-often-shoul/ Quotes to ponder: "Frequency of communication has nothing to do with frequency of communication." "The goal, I think, is to be missed when you don't communicate, not to be annoying when you do." "People tune you out when you have nothing to say and say it too often." Learn more about your ad choices. Visit megaphone.fm/adchoices

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 1738: Seth Godin invites readers to rethink how frequently they should share their work, emphasizing that the value of communication lies in consistency and relevance rather than volume. He highlights that building trust and connection comes from thoughtful, regular contributions that resonate with the audience, not from overwhelming them. Read along with the original article(s) here: https://seths.blog/2008/09/how-often-shoul/ Quotes to ponder: "Frequency of communication has nothing to do with frequency of communication." "The goal, I think, is to be missed when you don't communicate, not to be annoying when you do." "People tune you out when you have nothing to say and say it too often." Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the International Enneagram Association podcast, we continue listening to Gina Thomas's presentation about her study that studies the archetypes and their connections with the Enneagram. Gina is an Enneagram teacher who bridges the field with depth psychology, which studies myth, dream and symbol as a way to understand the psyche and she conducted four interviews with 13 focus groups, asking the participants to illustrate their type. She explores the transcendent function for Enneagram Types Six, Three and Four by interpreting each participant's drawings. Connect with us:Web: internationalenneagram.orgIEA Enneagram Experience 2025: ieaexperience.comJoin the email list: administration@internationalenneagram.orgIEA Conference Proposal Submission Information & Guidelines: internationalenneagram.org/wp-content/uploads/2024/07/2025-Proposal-Submission-Information-Guidelines.pdfIEA Global Podcast Proposal Submission Form: forms.gle/Q48QXSwQ3zDfDJaJAGina Thomas:Study: Archetype and Imagery in the EnneagramAephoria Partners:Web: aephoriapartners.comFB: Aephoria Partners Consulting

David Brand, housing reporter for WNYC and Gothamist, reports on Monday's meeting of the Rent Guidelines Board, which resulted in a vote to approve rent increases for stabilized apartments.

We're continuing our summer throwback series with a powerful episode that's simply too important to leave behind. While we're taking a short break this summer, we'll be resurfacing some of our most impactful conversations — the ones that made us think, challenged the status quo, and sparked meaningful dialogue. Today's rerun is one of those episodes. Originally aired as Episode 72, this conversation with Jessica Setnick dives headfirst into the controversial 2023 guidelines issued by the American Academy of Pediatrics (AAP). These guidelines made headlines — and not in a good way. Recommending behavioral interventions and even weight loss medications and surgery for children as young as 2, 12, and 13, respectively, the AAP ignited a firestorm of concern within the eating disorder treatment community. Jessica, a fierce advocate and long-time voice in the eating disorder field, joins me to unpack what these guidelines really say, why they're so troubling, and how they reflect a deeper cultural problem rooted in weight stigma. We question authority, untangle complex motivations (hello, pharma profits), and explore what weight-inclusive, ethical pediatric care should actually look like. In this episode, we're talking about: Why the AAP's new guidelines on pediatric weight management are sparking outrage in the eating disorder community. The alarming recommendations to introduce weight loss medications by age 12 and surgery by 13. The pervasive weight stigma built into these guidelines, including the problematic use of BMI as a screening tool. How profit motives, particularly from big pharma, may be influencing the creation of these “medical” guidelines. The real consequences of these interventions: malnutrition, stunted growth, cognitive impacts, and the risk of lifelong eating disorders. The false logic that shrinking a child's body will reduce weight stigma and why that belief is not just wrong, but dangerous. The importance of separating weight from health, and why any medical concerns should be treated based on symptoms, not size. How weight changes can be relevant when viewed contextually, but should never be the sole focus of medical intervention. Why trusting your gut and challenging medical advice is not only okay, but it might be necessary for protecting your child's wellbeing. Where to find weight-inclusive providers and what to ask when choosing a new pediatrician. Tweetable Quotes “Anyone who works in the eating disorder field at all – and probably many humans – knows multiple people, if not themselves, who have had failed weight loss interventions when they were children that then resulted in bigger problems.” – Jessica Setnick “The key is not to just single out the big kids. Any kid with an eating disorder should be evaluated. Any kid with a medical condition should be evaluated.” – Jessica Setnick “Shrinking children does not change their medical conditions.” – Jessica Setnick “‘Does my child have a medical condition, or are you saying my child is too big? Because if it's a medical condition, we'd like to get treatment independent of his size. But if you're saying his size is a problem, that's not a conversation I'm willing to have.'” – Jessica Setnick Resources AAP Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity News release for the AAP new guidelines Understanding Disordered Eating, Ep. 30: Eating Disorders are the Solution Not the Problem with Jessica Setnick, MS, RD, CEDRD-S Jessica on Facebook  Jessica on Instagram  Jessica Setnick: Understanding Nutrition Jessica's Website Grab my Journal Prompts Here! Looking for a speaker for an upcoming event? Let's chat! Accepting new clients in July - Find out if we're a good fit!   LEAVE A REVIEW + help someone who may need this podcast by sharing this episode. Be sure to sign up for my weekly newsletter here You can connect with me on Instagram @rachelleheinemann, through my website www.rachelleheinemann.com, or email me directly at rachelle@rachelleheinemann.com

In this special episode, we explore the newly released AMSN Staffing Guidelines designed to address the mounting pressures medical-surgical nurses face nationwide. The co-hosts welcome special guests Monica van der Zee and Kristi Campoe to break down what these guidelines mean for bedside nurses, nurse leaders, and healthcare systems alike. Discover how AMSN's evidence-based framework could serve as a roadmap toward safer staffing, improved patient care, and a more sustainable nursing workforce.   SPECIAL GUESTS Dr. Kristi Campoe, PhD, RN, CMSRN, CPHQ, sMBA has dedicated her life and career to creating supportive spaces that ignite confidence, foster growth, and inspire transformations. Now, with over 30 years of experience spanning medical-surgical nursing practice, academia,and healthcare innovation, she is a nationally recognized healthcare leader, scientist, and educator. She serves as Treasurer to the Academy of Medical-Surgical Nurses, Board of Directors, works as consultant in the device industry, and as adjunct faculty at Colorado Technical University. She served as the Board Liaison to the AMSN Nurse Staffing Task Force and will share insights today on AMSN's new recommendations. Monica van der Zee, BSN, RN, CMSRN has been working in health care for over 20 years, starting her career in a nursing home as a CNA. She presently serves as a Care Management Nurse in the Remote Physiological Monitoring Program at the University of Kansas Health System. Monica is passionate about advocacy, believing nurses can and should speak up for their patients, their communities, and themselves. She has served with the AMSN Legislative team and has been active in the Professionalism & Engagement Council and in unit and clinic level practice councils throughout her 10 years at the University of Kansas Health System.   MEET OUR CO-HOSTS Samantha Bayne, MSN, RN, CMSRN, NPD-BC is a nursing professional development practitioner in the inland northwest specializing in medical-surgical nursing. The first four years of her practice were spent bedside on a busy ortho/neuro unit where she found her passion for newly graduated RNs, interdisciplinary collaboration, and professional governance. Sam is an unwavering advocate for medical-surgical nursing as a specialty and enjoys helping nurses prepare for specialty certification.    Kellye' McRae, MSN-Ed, RN is a dedicated Med-Surg Staff Nurse and Unit Based Educator based in South Georgia, with 12 years of invaluable nursing experience. She is passionate about mentoring new nurses, sharing her clinical wisdom to empower the next generation of nurses. Kellye' excels in bedside teaching, blending hands-on training with compassionate patient care to ensure both nurses and patients thrive. Her commitment to education and excellence makes her a cornerstone of her healthcare team.   Marcela Salcedo, RN, BSN is a Floatpool nightshift nurse in the Chicagoland area, specializing in step-down and medical-surgical care. A member of AMSN and the Hektoen Nurses, she combines her passion for nursing with the healing power of the arts and humanities. As a mother of four, Marcela is reigniting her passion for nursing by embracing the chaos of caregiving, fostering personal growth, and building meaningful connections that inspire her work.   Eric Torres, ADN, RN, CMSRN is a California native that has always dreamed of seeing the World, and when that didn't work out, he set his sights on nursing.  Eric is beyond excited to be joining the AMSN podcast and having a chance to share his stories and experiences of being a bedside medical-surgical nurse.   Maritess M. Quinto, DNP, RN, NPD-BC, CMSRN is a clinical educator currently leading a team of educators who is passionately helping healthcare colleagues, especially newly graduate nurses. She was born and raised in the Philippines and immigrated to the United States with her family in Florida. Her family of seven (three girls and two boys with her husband who is also a Registered Nurse) loves to travel, especially to Disney World. She loves to share her experiences about parenting, travelling, and, of course, nursing!   Sydney Wall, RN, BSN, CMSRN has been a med surg nurse for 5 years. After graduating from the University of Rhode Island in 2019, Sydney commissioned into the Navy and began her nursing career working on a cardiac/telemetry unit in Bethesda, Maryland.  Currently she is stationed overseas, providing care for service members and their families.  During her free time, she enjoys martial arts and traveling.   

The All Local for July 1, 2025

AD Insider, in collaboration with the NIAAA and Human Kinetics, is proud to present an exclusive interview with Jeremy Schlitz, CAA, Athletic Director for the Madison Metropolitan School District (WI).In this special feature, Schlitz shares insights from his chapter on "Communication" in the newly released NIAAA's Guide to Interscholastic Athletic Administration - 2nd Edition.----------------------------------------------------...Inside the BookNIAAA's Guide to Interscholastic Athletic Administration - 2nd EditionEbook - Click HerePaperback - Click HereThe National Interscholastic Athletic Administrators Association (NIAAA) strives to preserve, enhance, and promote education-based athletics through the professional development of athletic administrators. The NIAAA's Guide to Interscholastic Athletic Administration, Second Edition, is the organization's primary text to further that mission.Designed for current and aspiring administrators, the text addresses the role and responsibilities of an administrator as well as the skills essential for managing an athletic program that provides quality sport opportunities for student-athletes. The second edition features many new contributors, all experienced professionals who bring fresh and diverse perspectives to the issues affecting today's administrators.Packed with advice, examples, and tools, this guide equips you to excel in the complex, demanding, and rewarding role of athletic administrator.Support the show

Rents are going up for nearly 1 million New Yorkers in rent-stabilized apartments after the Rent Guidelines Board approved increases Monday night. Starting in October, one-year leases will rise 3 percent, and two-year leases will go up 4.5 percent. Meanwhile, New Yorkers are getting their first look at ranked choice results from last week's primary election. Plus, a Staten Island family will be allowed to keep their pet pig temporarily while it receives medical treatment. But once it recovers, the mayor says the pig must move to the family's upstate home, where owning a pig as a pet is legal.

Podcast: PrOTect It All (LS 26 · TOP 10% what is this?)Episode: How to Harness AI Without Breaking Security or Corporate PoliciesPub date: 2025-06-30Get Podcast Transcript →powered by Listen411 - fast audio-to-text and summarizationIn this episode, host Aaron Crow dives deep into the fast-evolving world of AI automation and its impact on cybersecurity. Aaron breaks down practical, real-world ways security professionals can leverage AI to streamline their workflows without breaking data loss prevention policies or putting proprietary information at risk.  From drafting reports and playbooks to automating repetitive tasks and managing vulnerability data, Aaron offers actionable advice for using both public AI tools like ChatGPT and more advanced private AI models. He also addresses common fears CISOs and business leaders have about unsanctioned AI use in the workplace and shares tips for staying safe and compliant while taking advantage of AI's efficiencies.  Whether you're in a large enterprise or a lean team with limited resources, you'll come away with a fresh perspective on how to use AI responsibly to work smarter and protect your organization. Plus, Aaron invites listeners to share their own creative AI use cases and lessons learned. Let's jump in and explore how to protect it all as AI advances. Key Moments :  01:20 AI's Rising Role in Media 03:22 Guidelines for Using AI Safely 07:06 "AI Integration and Automation Strategies" 10:03 Automating Windows Management Tasks 14:29 Exploring AI for Personal Tasks Connect With Aaron Crow: Website: www.corvosec.com  LinkedIn: https://www.linkedin.com/in/aaronccrow   Learn more about PrOTect IT All: Email: info@protectitall.co  Website: https://protectitall.co/  X: https://twitter.com/protectitall  YouTube: https://www.youtube.com/@PrOTectITAll  FaceBook:  https://facebook.com/protectitallpodcast    To be a guest or suggest a guest/episode, please email us at info@protectitall.co   Please leave us a review on Apple/Spotify Podcasts: Apple   - https://podcasts.apple.com/us/podcast/protect-it-all/id1727211124 Spotify - https://open.spotify.com/show/1Vvi0euj3rE8xObK0yvYi4The podcast and artwork embedded on this page are from Aaron Crow, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.

The city's Rent Guidelines Board is voting Monday on proposed rent increases for over a million stabilized apartments. Meanwhile, New York City is investing in new mental health clubhouses to support people with serious mental illness. And police are investigating a shooting that injured two teenage girls near the Stonewall Inn just hours after the Pride parade.

Police say a 16-year-old girl is in critical condition after being shot in the head near the Stonewall Inn as Pride celebrations wrapped up Sunday night. A 17-year-old was also shot and is in stable condition. Meanwhile, the MTA will stop selling MetroCards by the end of the year as it completes its shift to the OMNY tap-to-pay system. A planned four percent fare hike could also raise the cost of a single ride to $3. Plus, the city's Rent Guidelines Board is set to vote Monday night on potential increases for rent-stabilized apartments. WNYC's David Brand joins us to explain what's at stake.

Listen as expert faculty answer your most pressing questions on optimizing immunization in clinical practice.Topics covered include:Practical methods for improving confidence in vaccinesHow to educate patients on vaccine development and safety monitoring Effective strategies to tailor recommendations, such as motivational interviewingWays to navigate clinical encounters and address vaccine hesitancyPresenters:Robert H. Hopkins, Jr., MD, MACPProfessor of Internal Medicine and PediatricsUniversity of Arkansas for Medical SciencesCollege of MedicineLittle Rock, ArkansasLitjen (L.J.) Tan, MS, PhDChief Policy and Partnership Office, Immunize.orgChair, National Adult Influenza Immunization SummitCo-Chair, Global Influenza InitiativeSt Paul, MinnesotaLink to full program: https://bit.ly/3I5jBh0Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Miscarriage affects one in four pregnancies, yet many mums are left with little support or clarity around what comes next.In this Check-In Tuesday episode, Dr Renee White unpacks the newly released national guidelines for miscarriage and early pregnancy loss in Australia. Developed by RANZCOG, these are the first of their kind and aim to bring consistency and compassion to miscarriage care.Renee walks through the key updates from medical definitions to emotional support and shares why this is a long-overdue step toward better care for women and families.You'll hear about:What the new guidelines cover and how they'll impact careWhy changing the definition of recurrent miscarriage mattersThe role of language, empathy and communication in clinical settingsWhy location shouldn't determine the quality of care mums receiveWhat's still missing and where improvement is neededResources and Support

The JournalFeed podcast for the week of 23-27, 2025.These are summaries from just 2 of the 5 articles we cover every week! For access to more, please visit JournalFeed.org for details about becoming a member.Wednesday Spoon Feed:Bayesian analysis of the use of EpiDex in bronchiolitis demonstrates a reduced probability of hospitalization for bronchiolitis, although highly skeptical clinicians may require additional evidence.Friday Spoon Feed:Over half of transferred patients with facial fractures don't need treatment or admission. This study proposes smart, evidence-based guidelines – Facial Injury Guidelines, or FIG – to help healthcare systems save money, time, and beds (and maybe a few ambulance rides), pending future validation.

True healing in relationships begins when we choose kindness, compassion, and forgiveness just as Christ has forgiven us.

At this rate, the Blue Jays are likely to be summer buyers. Arden and Ben discuss what pitching the Jays will need (01:31) before wondering about offensive upgrades (27:49) and the role of this front office (40:33).This podcast is produced and sound engineered by Christian Ryan and hosted by Ben Nicholson-Smith and Arden Zwelling.Contact us: attheletters@sportsnet.caAudio Credits: MLB.comThe views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate. 

Which tests can be used to diagnose type 2 diabetes? When should injectable medications for type 2 diabetes be started? These are just some of the questions clinicians may have when diagnosing and treating type 2 diabetes in adults. Author Rita Kalyani, MD, MHS, of Johns Hopkins University School of Medicine, discusses this and more with JAMA Senior Editor Karen Lasser, MD, MPH. Related Content: Diagnosis and Treatment of Type 2 Diabetes in Adults

In this essential episode of Parallax, Dr Ankur Kalra is joined by Dr Michelle O'Donoghue, cardiologist at Brigham and Women's Hospital and co-author of the recently updated AHA/ACC acute coronary syndrome guidelines. Together, they explore the revolutionary changes reshaping ACS management in 2025. Dr O'Donoghue shares insights from the landmark guideline development process that unified non-ST elevation ACS and ST elevation MI recommendations into a single comprehensive document. The conversation covers game-changing updates including new risk stratification approaches, the shift toward selective invasive strategies, and the introduction of bivalirudin as an alternative anticoagulation option. The discussion highlights the groundbreaking "lower is better" approach to LDL management with new targets below 55 mg/dL, evolving antiplatelet therapy strategies, and the emerging role of ticagrelor monotherapy. Dr O'Donoghue also addresses future directions in cardiovascular care, from GLP-1 agonists to mechanical circulatory support devices, emphasizing how these guidelines represent a fundamental shift toward more personalized, evidence-based ACS management. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

Today's Headlines: President Trump hinted the U.S. might bomb Iran, while evacuations from Israel continue and tensions rise with Iran warning of “irreparable damage.” European diplomats plan to meet with Iran as military buildup in the region grows. Back home, the Federal Reserve held interest rates steady amid signs of slower growth, and Trump mocked Chair Powell, suggesting he could run the Fed himself. Meanwhile, the Senate passed the GENIUS Act, allowing banks to treat crypto stablecoins as assets. The Pentagon deployed 2,000 more National Guard troops to L.A. with little explanation. The Supreme Court upheld Tennessee's ban on gender-affirming care for minors, while a separate ruling preserved the right of trans and nonbinary Americans to request accurate passport markers. Finally, new federal dietary guidelines are expected to drop previous limits on daily alcohol intake, despite cancer risks. Resources/Articles mentioned in this episode: AP News: Iran's leader rejects calls to surrender and warns that intervention would harm the US  CNBC: Fed decision recap: Central bank signals stagflation fears, Powell says Fed ‘well positioned to wait' on rates CNBC: Trump says 'Too Late' Powell must lower interest rates after weak ADP jobs report  Axios: Senate passes GENIUS Act despite crypto corruption concerns CBS News: 2,000 more National Guard troops being deployed to Los Angeles, Pentagon says NBC News: Supreme Court upholds Tennessee ban on transgender youth medical care AP News: Judge says government can't limit passport sex markers for many transgender, nonbinary people Reuters: Exclusive: US to drop guidance to limit alcohol to one or two drinks per day, sources say Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

In this 310th episode I welcome Dr. Annemarie Thompson, head of the working group that put out the new AHA/ACC Guidelines for the perioperative cardiovascular management for noncardiac surgery, and Drs. Jochen Steppan and Giancarlo Suffredini, cardiac anesthesiologists, to talk about the new iteration of the guidelines. We go through the algorithm in detail and talk about the evidence behind it and how to use biomarkers. Our Sponsors:* Check out Eko: https://ekohealth.com/ACCRAC* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com* Check out Factor: https://factormeals.com/accrac50off* Check out Truelearn and use my code ACCRAC for a great deal: https://truelearn.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy